Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II

被引:8
作者
Gaudet, Mia M. [1 ]
Deubler, Emily [1 ]
Diver, W. Ryan [1 ]
Puvanesarajah, Samantha [1 ]
Patel, Alpa, V [1 ]
Gansler, Ted [1 ]
Sherman, Mark E. [2 ]
Gapstur, Susan M. [1 ]
机构
[1] Amer Canc Soc, Behav & Epidemiol Res Program, 250 Williams St, Atlanta, GA 30303 USA
[2] Mayo Clin, Dept Epidemiol & Lab Med, Coll Med, Jacksonville, FL USA
关键词
Breast cancer; Benign breast disease; Mammography; Disease heterogeneity; Risk factors; ESTROGEN-PLUS-PROGESTIN; MAMMOGRAPHIC DENSITY; TUMOR CHARACTERISTICS; POSTMENOPAUSAL WOMEN; ALCOHOL-CONSUMPTION; INTERVAL CANCERS; HORMONE-THERAPY; SURVIVAL; HISTORY; AGE;
D O I
10.1007/s10549-020-06025-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Identifying risk factors for women at high risk of symptom-detected breast cancers that were missed by screening would enable targeting of enhanced screening regimens. To this end, we examined associations of breast cancer risk factors by mode of detection in screened women from the Cancer Prevention Study (CPS)-II Nutrition Cohort. Methods Among 77,206 women followed for a median of 14.8 years, 2711 screen-detected and 1281 symptom-detected breast cancer cases were diagnosed. Multivariable-adjusted associations were estimated using joint Cox proportional hazards regression models with person-time calculated contingent on screening. Results Factors associated with higher risks of symptom-detected and screen-detected breast cancer included current combined hormone therapy (HT) use (HR 2.07, 95% CI 1.72-2.48 and 1.45, 1.27-1.65, respectively) and history of benign breast disease (1.85, 1.64-2.08 and 1.43, 1.31-1.55, respectively). Current estrogen-only HT use was associated with symptom-detected (1.40, 1.15-1.71) but not screen-detected (0.95, 0.83-1.09) breast cancer. Higher risk of screen-detected but not symptom-detected breast cancer was observed for obese vs. normal body mass index (1.22, 1.01-1.48 and 0.76, 0.56-1.01, respectively), per 3 h/day sitting time (1.10, 1.04-1.16 and 0.97, 0.89-1.06, respectively), and >= 2 drinks per day vs. nondrinker (1.40, 1.16-1.69 and 1.27, 0.97-1.66, respectively). Conclusions Differences in risk factors for symptom-detected vs. screen-detected breast cancer were observed and most notably, use of combined and estrogen-only HT and a history of benign breast disease were associated with increased risk of symptomatic detected breast cancer. Impact If confirmed, these data suggest that such women may benefit from more intensive screening to facilitate early detection.
引用
收藏
页码:791 / 805
页数:15
相关论文
共 53 条
  • [1] The Many Faces of Obesity and Its Influence on Breast Cancer Risk
    Agurs-Collins, Tanya
    Ross, Sharon A.
    Dunn, Barbara K.
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [2] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
    Anderson, GL
    Limacher, M
    Assaf, AR
    Bassford, T
    Beresford, SAA
    Black, H
    Bonds, D
    Brunner, R
    Brzyski, R
    Caan, B
    Chlebowski, R
    Curb, D
    Gass, M
    Hays, J
    Heiss, G
    Hendrix, S
    Howard, BV
    Hsia, J
    Hubbell, A
    Jackson, R
    Johnson, KC
    Judd, H
    Kotchen, JM
    Kuller, L
    LaCroix, AZ
    Lane, D
    Langer, RD
    Lasser, N
    Lewis, CE
    Manson, J
    Margolis, K
    Ockene, J
    O'Sullivan, MJ
    Phillips, L
    Prentice, RL
    Ritenbaugh, C
    Robbins, J
    Rossouw, JE
    Sarto, G
    Stefanick, ML
    Van Horn, L
    Wactawski-Wende, J
    Wallace, R
    Wassertheil-Smoller, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14): : 1701 - 1712
  • [3] Digital Breast Tomosynthesis: A New Diagnostic Method for Mass-Like Lesions in Dense Breasts
    Bian, Tiantian
    Lin, Qing
    Cui, Chunxiao
    Li, Lili
    Qi, Chunhua
    Fei, Jie
    Su, Xiaohui
    [J]. BREAST JOURNAL, 2016, 22 (05) : 535 - 540
  • [4] Impact of Risk Factors on Different Interval Cancer Subtypes in a Population-Based Breast Cancer Screening Programme
    Blanch, Jordi
    Sala, Maria
    Ibanez, Josefa
    Domingo, Laia
    Fernandez, Belen
    Otegi, Arantza
    Barata, Teresa
    Zubizarreta, Raquel
    Ferrer, Joana
    Castells, Xavier
    Rue, Montserrat
    Salas, Dolores
    [J]. PLOS ONE, 2014, 9 (10):
  • [5] Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133
  • [6] Mammographic density and the risk and detection of breast cancer
    Boyd, Norman F.
    Guo, Helen
    Martin, Lisa J.
    Sun, Limei
    Stone, Jennifer
    Fishell, Eve
    Jong, Roberta A.
    Hislop, Greg
    Chiarelli, Anna
    Minkin, Salomon
    Yaffe, Martin J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (03) : 227 - 236
  • [7] Mammographic features associated with interval breast cancers in screening programs
    Boyd N.F.
    Huszti E.
    Melnichouk O.
    Martin L.J.
    Hislop G.
    Chiarelli A.
    Yaffe M.J.
    Minkin S.
    [J]. Breast Cancer Research, 16 (4)
  • [8] Assessing within-woman changes in mammographic density: a comparison of fully versus semi-automated area-based approaches
    Busana, Marta Cecilia
    De Stavola, Bianca L.
    Sovio, Ulla
    Li, Jingmei
    Moss, Sue
    Humphreys, Keith
    dos-Santos-Silva, Isabel
    [J]. CANCER CAUSES & CONTROL, 2016, 27 (04) : 481 - 491
  • [9] Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk
    Byrne, Celia
    Ursin, Giske
    Martin, Christopher F.
    Peck, Jennifer D.
    Cole, Elodia B.
    Zeng, Donglin
    Kim, Eunhee
    Yaffe, Martin D.
    Boyd, Norman F.
    Heiss, Gerardo
    McTiernan, Anne
    Chlebowski, Rowan T.
    Lane, Dorothy S.
    Manson, Joann E.
    Wactawski-Wende, Jean
    Pisano, Etta D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (09):
  • [10] The American Cancer Society cancer prevention study II nutrition cohort - Rationale, study design, and baseline characteristics
    Calle, EE
    Rodriguez, C
    Jacobs, EJ
    Almon, ML
    Chao, A
    McCullough, ML
    Feigelson, HS
    Thun, MJ
    [J]. CANCER, 2002, 94 (09) : 2490 - 2501